Research digest · regulatory lens
Ipamorelin is the first growth hormone secretagogue precise enough to pulse GH without the cortisol — and the record on it is fascinating precisely because it was never approved.
A forward-looking, fully cited reading of what the studies measured, what the one human trial actually showed, and exactly where this peptide sits with the FDA and WADA today.
Start here
Ipamorelin is a tiny lab-made peptide — five amino acids strung together — that tells the pituitary gland to release a short pulse of growth hormone (GH), the body's own building-and-repair signal. What makes it stand out is its precision: in animal studies it raised GH cleanly without also spiking cortisol or prolactin, the stress and milk hormones that older peptides in its family kicked up alongside it.
Here is the honest headline. Ipamorelin has never been approved as a medicine anywhere in the world. The single human trial that reached the testing stage — for slow bowels after surgery — did not beat placebo. It is sold only as a research chemical, and it is banned in sport. People in research-use communities report better sleep and faster recovery, and you can read exactly what they report — including the downsides — on the effects page. This site is a digest of the published science, not a clinic and not a store. Every number below is tied to the study that measured it.
What the science actually established
The defining finding came first. In its 1998 founding characterization, ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine — with a swine ED50 of 2.3 nmol/kg, comparable to the older peptide GHRP-6 — yet it did not raise ACTH or cortisol above baseline even at doses more than 200-fold higher than its GH-releasing dose [1]. That single result is why ipamorelin is called selective: it does one job, GH release, and largely leaves the adrenal and prolactin axes alone.
It works by activating the GHS-R1a receptor — the ghrelin receptor, the same docking site the body's natural "hunger hormone" uses — on the pituitary's GH-producing cells [1]. That makes it a ghrelin mimetic: a synthetic stand-in for a hormone the body already makes. Because it triggers GH through a different pathway than GHRH (growth-hormone-releasing hormone), researchers pair it with GHRH-style peptides; the two together can drive a larger pulse than either alone, a class-level principle shown for related peptide pairs [10][11].
The human evidence is thin — and that is the real story
Most of what is known about ipamorelin comes from animals. The human file is small and largely negative, and a forward-looking read says so plainly rather than overselling it.
A human pharmacokinetic study in healthy male volunteers (n=8 per dose, single 15-minute IV infusions of 4.21–140.45 nmol/kg) found clean, dose-proportional kinetics with a terminal half-life of about 2 hours, and a single discrete GH pulse peaking near 40 minutes after dosing [2]. Then the only published Phase 2 trial — 114 adults given 0.03 mg/kg IV twice daily after bowel surgery — missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. No Phase 3 trial followed, and no approval ever came. The Ipamorelin research page walks through every study; the open question of human efficacy is the next chapter, not a finished verdict.
Where ipamorelin stands today
Regulatory status is the figure that matters most here, so this site leads with it. Ipamorelin is not FDA-approved for any indication, and in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting — tightening, not loosening, compounding-pharmacy access [7]. It is prohibited in sport at all times under the WADA Prohibited List (category S2), and accredited labs can detect it in urine [9]. The full picture is on the dedicated is ipamorelin fda approved page.
That status is not a footnote — it is the headline. A peptide this pharmacologically elegant has, so far, produced an elegant mechanism and a short list of mostly-negative human results. This digest reads that record straight: the bright confirmed points kept apart from the speculative ones, and the regulatory line read directly from the register. The benefits and downsides people report are gathered on the Ipamorelin effects page, and every source we cite is collected in the Ipamorelin references list.